Longeveron Inc. 8-K

What Happened
Longeveron Inc. filed an 8-K reporting that director Richard Kender resigned from the Board and the Audit Committee effective March 3, 2026. The resignation left the company temporarily out of compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires an audit committee of at least three independent directors with at least one audit committee financial expert. On March 4, 2026 the Board appointed existing director Dr. Roger Hajjar to the Audit Committee to restore the three-independent-member requirement, but no current member qualifies as an audit committee financial expert.

Key Details

• Resignation: Richard Kender resigned effective March 3, 2026; he left to assume the role of Executive Chairman and Interim CEO at Seres Therapeutics (announced March 2, 2026). He stated the resignation was not due to any disagreement with Longeveron.
• Audit committee appointment: Dr. Roger Hajjar was added to the Audit Committee on March 4, 2026 to restore three independent members.
• Financial expert gap: After the appointment, the Audit Committee still lacks a member who qualifies as an “audit committee financial expert.”
• Cure plan: Longeveron plans to appoint, or submit for shareholder election, at least one director who is both independent and an audit committee financial expert by the earlier of its next annual meeting or within the 180-day cure period under Nasdaq rules.

Why It Matters
This is a governance and compliance issue rather than an operational or financial disclosure. Nasdaq rules require a properly constituted audit committee; the company has notified Nasdaq and taken a step to restore independence but still must add an audit committee financial expert within the stated cure period. Investors should note the change in Board composition and the company’s plan to remedy the compliance gap; the filing does not report any disagreements with management or operational impacts.